Complex brain and cardiac organoids for rapid testing of nootropics and caffeine

Overview

Retagen Inc. provides advanced organoid tissue models designed to accelerate the testing of nootropics and caffeine for cognitive and energy applications. These complex in vitro tissues combine multiple relevant cell types, such as neurons and astrocytes for brain models, to better replicate in vivo biological responses compared to traditional single-cell assays. The platform enables researchers to evaluate compound effects on cell signaling, viability, mitochondrial energetics, and downstream interactions in both healthy and stressed conditions. By offering a rapid, reproducible, and ethically responsible alternative to animal testing, Retagen's organoids help streamline pharmaceutical and nutraceutical research and development.

Technical specifications

• Multi-cell-type organoids combining neurons, astrocytes, and other relevant cell types to model complex brain tissue behavior
• Cardiac tissue models available for parallel assessment of cardiac function and toxicity
• Validated assays including neurite growth and trimming, arborization, stem cell differentiation, and astrocyte-to-neuron associations
• Metabolic and viability assessments using ATP production assays, mitotracker dyes, and Ca+2 flux measurements
• Mid-throughput analysis performed on a Biotek Cytation platform for efficient compound screening
• Stress and disease modeling capabilities to test compounds under both healthy and pathological conditions
• Reproducible results demonstrating greater complexity and closer reflection of in vivo responses than conventional in vitro models

Technology readiness level

Retagen's organoid tissues, including both brain and cardiac models, have undergone validation for vitality, longevity, and drug-like molecule interactions. Current data demonstrates reproducible performance and enhanced biological complexity compared to standard in vitro approaches. The brain organoid models have been assessed in stress and depression research contexts, yielding results consistent with in vivo findings. While adenosine A2 receptor activity and caffeine-specific interactions have not yet been explored, the existing tissue platform is positioned for immediate application in nootropic and caffeine testing. A proposed one-year collaborative validation program with Seneca College's Applied Research Program aims to expand testing capabilities and generate comprehensive data on compound efficacy and safety profiles.